Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease

European Journal of Surgery

Volumn 164, Issue 12, 1998, Pages 903-909

  Feagan, Brian G ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LCTRG/RRI   (Canada)

Author keywords

5 ASA; Budesonide; Crohn's disease; Inflammatory bowel disease

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BUDESONIDE; GLUCOCORTICOID; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG RESISTANCE; ENTERITIS; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0032429948     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241598750005066     Document Type: Review

References (29)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moeity of sulphasalazine. Lancet 1977; ii: 892-895.
2. Brimblecombe R. Mesalazine: a global safety evaluation. Scand J Gastroenterol 1990; 172; 66.
3. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman RA. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678.
4. Ewe K, Herfarth C, Malchow H, Jesdinsky JH. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulphasalazine prophylaxis: a multicenter trial. Digestion 1989; 42: 224-232.
5. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-372.
6. Feagan BG, McDonald JW, Koval JJ. Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. Gastroenterology 1996; 110: 275-283.
7. Feagan BG, Rochon J, Fedorak RN, et al. for the North American Crohn's Study Group. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-297.
8. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-841.
9. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337: 536-542.
10. Lochs H, Fleig WE, Mortensen PB, Bauer P and the ECCDS VI Study Group. Prophylaxis of postoperative relapse in Crohn's disease with mesalazine (Pentasa®) in comparison to placebo. Gastroenterology 1997; 112, 4: A1027.
11. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995; 109: 404-413.
12. Mahida YR, Jewell DP. Slow-release 5-amino-salicyclic acid (Pentasa®) for the treatment of active Crohn's disease. Digestion 1990; 45: 88-92.
13. Maier K, Frick H-J, von Gaisberg U, Teufel T, Klotz U. Clinical efficacy of oral mesalazine in Crohn's disease. Canadian Journal of Gastroenterology 1990; 4: 13-18.
14. Malchow H, Ewe K, Brandes JW, et al European Cooperative Crohn's Disease Study (ECCDS). Results of drug treatment. Gastroenterology 1984; 86: 249-266.
15. Martin F, Sutherland L, Beck IT, et al. Oral 5-ASA versus prednisone in short term treatment of Crohn's disease: A multicentre controlled trial. Canadian Journal of Gastroenterology 1990; 4: 452-457.
16. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692-698.
17. Modigliani R, Colombel JF, Dupas J-L, et al. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110: 688-693.
18. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
19. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16 week double-blind, placebo-controlled, multicentre study with Pentasa®. Scand J Gastroenterol 1987; 22: 877-883.
20. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-845.
21. Schölmerich J, Jenns H, Hartmann F, Döpfer H and the German 5-ASA Study group. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Canadian Journal of Gastroenterology 1990; 4: 446-451.
22. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994; 107: 632-633.
23. Singleton JW, Hanauer SB, Gitnick GL, et al. and the Pentasa® Crohn's Disease Study Group. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology 1993; 104: 1293-1301.
24. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847-869.
25. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. Gastroenterology 1997; 112: 1069-1077.
26. Sutherland LR, Ross DE, Beck PL. Alternatives to sulphasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases 1997; 3: 65-78.
27. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalamine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterology 1994; 89: 2116-2124.
28. Thomsen OO, Cortot A, Jewell D, et al. Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week international randomized, double-blind multicenter trial. Gastroenterology 1997; 112: A1104.
29. Thomson A. Mesalazine (Mesasal/Claversal) 1.5 gbd vs placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995; 9: 673-683.